Physician profile
Joseph A Jamison
NPI 1497720114
$8,888.96
in general payments reported to CMS, 2019-2025
40 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,555 · 2020: $1,376 · 2021: $2,469 · 2022: $1,454 · 2023: $1,284 · 2024: $532 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,034.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,756.12 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,196.87 | 2019-2024 | Trelegy Ellipta, Shingrix, Bexsero |
| Astrazeneca Pharmaceuticals LP | $888.03 | 2019-2023 | Fasenra, Breztri |
| Novo Nordisk INC | $514.02 | 2019-2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $497.96 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $491.28 | 2019-2022 | |
| Amgen INC. | $460.34 | 2019-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $417.91 | 2019-2023 | Vaxelis, Vaxneuvance, Rotateq |
| Takeda Pharmaceuticals U.S.A., INC. | $327.06 | 2020-2022 | |
| Abbott Laboratories | $294.89 | 2022-2025 | Freestyle Libre 3 |
| Abbvie INC. | $293.24 | 2020-2022 | |
| Lilly USA, LLC | $237.55 | 2019-2024 | Mounjaro, Jardiance, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $209.20 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $145.25 | 2021 | |
| Exact Sciences Corporation | $119.48 | 2023-2025 | Cologuard Collection Kit |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Jamison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.